About beyondspring inc - BYSI
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in Florham Park, NJ.
BYSI At a Glance
BeyondSpring, Inc.
100 Campus Drive
Florham Park, New Jersey 07932
| Phone | 1-646-305-6387 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -7,992,000.00 | |
| Sector | Health Technology | Employees | 44 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BYSI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.976 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.005 |
BYSI Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -181,636.364 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BYSI Liquidity
| Current Ratio | 1.538 |
| Quick Ratio | 1.538 |
| Cash Ratio | 0.925 |
BYSI Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -28.127 |
| Return on Equity | N/A |
| Return on Total Capital | 26.61 |
| Return on Invested Capital | N/A |
BYSI Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -1.005 |
| Total Debt to Total Assets | 1.234 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |